Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

38.12 -0.42 (-1.09%)
Streaming Delayed Price Updated: 3:31 PM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >
Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Where MoonLake Stands With Analysts
Via Benzinga
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
Via Investor's Business Daily
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
The Latest Analyst Ratings for MoonLake
Via Benzinga
Expert Ratings for MoonLake
Via Benzinga
10 Analysts Have This to Say About MoonLake
Via Benzinga
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
These 8 Stocks Are Outperforming Nvidia In 2023
Carvana has surged 1,001%, leading huge winners this year. 
Via Investor's Business Daily
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
A competitor's clinical trial stumble may be benefiting MoonLake. 
Via The Motley Fool
Analyst Expectations for MoonLake's Future
Via Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
Casey's General Stores, Cognyte Software, Beauty Health And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones gaining around 90 points on Tuesday. Here are some big stocks recording gains in today’s session. Shengfeng Development Limited (NASDAQ: SFWL) shares jumped... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%
The companies are both working on treatments for a rare skin disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
Via Benzinga
The 7 Most Promising Momentum Stocks to Own Now
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility. 
Via InvestorPlace
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
Price Target For MoonLake Doubled: Analyst Says Lead Program Has 'Best-In-Class Profile'
HC Wainwright has increased the price target for MoonLake Immunotherapeutics (NASDAQ: MLTX) from $37 to $75  
Via Benzinga
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
Benzinga 
Via Benzinga
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for... 
Via Benzinga
10 Short Squeeze Stocks To Watch: Asset Entities, Lightning eMotors, Bullfrog AI, Carvana And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
$40M Bet On MoonLake Immunotherapeutics? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.